In the AML/M5‐sh‐RCN1 group, Cluster 0 accounted for 37% of the total, compared to 26% in the AML/M5‐sh‐ctrl group, while Cluster 3 accounted for 4% of the total, down from 11% in the control group (Fig. 2B). The gene discussed is RCN1; the disease is acute myeloid leukemia.